guest ::
| Home > Publications Database > B21 Characterisation Of Mice Overexpressing Mutant Huntingtin Lacking The Spine Morphogenesis Regulator Kalirin-7 > print |
| Home > Publications Database > B21 Characterisation Of Mice Overexpressing Mutant Huntingtin Lacking The Spine Morphogenesis Regulator Kalirin-7 > print |
| 001 | 138141 | ||
| 005 | 20230915101157.0 | ||
| 024 | 7 | _ | |a 10.1136/jnnp-2014-309032.49 |2 doi |
| 024 | 7 | _ | |a pmid:28850992 |2 pmid |
| 024 | 7 | _ | |a 0022-3050 |2 ISSN |
| 024 | 7 | _ | |a 0266-8637 |2 ISSN |
| 024 | 7 | _ | |a 0368-329X |2 ISSN |
| 024 | 7 | _ | |a 1468-330X |2 ISSN |
| 037 | _ | _ | |a DZNE-2020-04463 |
| 041 | _ | _ | |a ger |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Ernst, A. |0 P:(DE-2719)9000999 |b 0 |e First author |u dzne |
| 245 | _ | _ | |a B21 Characterisation Of Mice Overexpressing Mutant Huntingtin Lacking The Spine Morphogenesis Regulator Kalirin-7 |
| 260 | _ | _ | |a London |c 2017 |b BMJ Publishing Group |
| 264 | _ | 1 | |3 online |2 Crossref |b BMJ |c 2014-09-17 |
| 264 | _ | 1 | |3 print |2 Crossref |b BMJ |c 2014-09-01 |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1594283687_29753 |2 PUB:(DE-HGF) |x Editorial |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a The BEMED study (BMJ 2016; 352: DOI 10.1136) was designed as multi-centric, double-blind, plaebo-controlled study in patients with Menière's disease. It should compare a low-level (2 × 24 mg/d) vs. high-level (3 × 48 mg/d) betahstine intake vs. placebo. The primary endpoint was the 'number of vertigo attacks lasting longer than 20 min as documented in a patient's diary'. The main finding of the study was that betahistine did not significantly better reduced the number of vertigo attacks than placebo. Therefore, the BEMED study should be critically discussed in the present paper. |
| 536 | _ | _ | |a 344 - Clinical and Health Care Research (POF3-344) |0 G:(DE-HGF)POF3-344 |c POF3-344 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a Betahistine |0 X32KK4201D |2 NLM Chemicals |
| 650 | _ | 2 | |a Adolescent |2 MeSH |
| 650 | _ | 2 | |a Adult |2 MeSH |
| 650 | _ | 2 | |a Aged |2 MeSH |
| 650 | _ | 2 | |a Aged, 80 and over |2 MeSH |
| 650 | _ | 2 | |a Betahistine: therapeutic use |2 MeSH |
| 650 | _ | 2 | |a Dose-Response Relationship, Drug |2 MeSH |
| 650 | _ | 2 | |a Double-Blind Method |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Germany |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Meniere Disease: classification |2 MeSH |
| 650 | _ | 2 | |a Meniere Disease: diagnosis |2 MeSH |
| 650 | _ | 2 | |a Meniere Disease: drug therapy |2 MeSH |
| 650 | _ | 2 | |a Middle Aged |2 MeSH |
| 650 | _ | 2 | |a Young Adult |2 MeSH |
| 700 | 1 | _ | |a Schlattmann, P. |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Waldfahrer, F. |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Westhofen, M. |0 P:(DE-HGF)0 |b 3 |
| 773 | 1 | 8 | |a 10.1136/jnnp-2014-309032.49 |b : BMJ, 2014-09-01 |n Suppl 1 |p A16-A16 |3 journal-article |2 Crossref |t Journal of Neurology, Neurosurgery & Psychiatry |v 85 |y 2014 |x 0022-3050 |
| 773 | _ | _ | |a 10.1136/jnnp-2014-309032.49 |g Vol. 96, no. 8, p. A16 - A16 |0 PERI:(DE-600)1480429-3 |n Suppl 1 |q 96:8 |t Journal of neurology, neurosurgery, and psychiatry |v 85 |y 2014 |x 0022-3050 |
| 909 | C | O | |o oai:pub.dzne.de:138141 |p VDB |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 0 |6 P:(DE-2719)9000999 |
| 913 | 1 | _ | |a DE-HGF |b Forschungsbereich Gesundheit |l Erkrankungen des Nervensystems |1 G:(DE-HGF)POF3-340 |0 G:(DE-HGF)POF3-344 |2 G:(DE-HGF)POF3-300 |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2017 |
| 915 | _ | _ | |a National-Konsortium |0 StatID:(DE-HGF)0430 |2 StatID |d 2022-11-23 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2022-11-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-23 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J NEUROL NEUROSUR PS : 2021 |d 2022-11-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-23 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-23 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b J NEUROL NEUROSUR PS : 2021 |d 2022-11-23 |
| 920 | 1 | _ | |0 I:(DE-2719)1240015 |k AG N.N. 3 |l AG N.N. |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)1240015 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|